Dihydroimidazo[1,2-a]pyrimidine derivatives, methods of preparing said compounds and pharmaceutical compositions constaining said compounds
申请人:Yoshitomi Pharmaceutical Industries, Ltd.
公开号:EP0163240A2
公开(公告)日:1985-12-04
A dihydroimidazo [1, 2-a] pyrimidine derivative of the formula:
wherein R is hydrogen, C1-5 alkyl, heteroaryl, 2, 1, 3-benzoxadiazolyl or phenyl which may be substituted by a substituent selected from halogen, C1-4 alkyl, trifluoromethyl, C1-4 alkoxy, nitro and cyano;
R' is cyano, C1-4 alkoxy-carbonyl or -COOCH (R5) CH2R6 [wherein R5 is hydrogen or aryl and R6 is C1-4 alkoxy or -N (Ra) (Rb) (wherein each of Ra and Rb is C1-4 alkyl or aralkyl, or Ra and Rb together with the adjacent nitrogen atom form a heterocycle)];
R2 is C1-4 alkyl, hydroxymethyl, acetoxymethyl, di-C1-4 alkoxy-methyl, C1-4 alkyl-carbamoyloxymethyl or hydroxyimino-methyl;
R3 is C1-4 alkyl, formyl, carboxyl, nitro, -N (R7) (R8) (wherein each of R7 and RB is hydrogen, C1-8 alkyl, aryl, aralkyl or acyl, or R7 and RB together with the adjacent nitrogen atom form a heterocycle), -OR9 or -SR10 (wherein each of R9 and R10 is hydrogen, C1-8 alkyl, aralkyl or acyl);
R4 is hydrogen or -(CH2)mN (Rc) (Rd) (wherein each of Rc and Rd is C1-4 alkyl or aralkyl, or Rc and Rd together with the adjacent nitrogen atom form a heterocycle and m is 1 to 3;
n is 0 or 1 to 3, inclusive of an optical isomer thereof, a diastereomer thereof and compounds selected from the group consisting of pharmaceutically acceptable acid addition salt forms thereof, hydrate forms thereof and mixtures thereof, methods of preparing said compounds and pharmaceutical compositions containing said compounds are disclosed.
The dihydroimidazo [1, 2-a] pyrimidine derivatives are useful as drugs for the treatment of coronary and cerebral circulatory diseases.
式中的二氢咪唑并[1,2-a]嘧啶衍生物:
其中 R 是氢、C1-5 烷基、杂芳基、2,1,3-苯并噁二唑基或苯基,可被选自卤素、C1-4 烷基、三氟甲基、C1-4 烷氧基、硝基和氰基的取代基取代;
R' 是氰基、C1-4 烷氧基-羰基或 -COOCH (R5) CH2R6 [其中 R5 是氢或芳基,R6 是 C1-4 烷氧基或 -N (Ra) (Rb)(其中 Ra 和 Rb 各自是 C1-4 烷基或芳烷基,或 Ra 和 Rb 与相邻的氮原子一起形成杂环)];
R2 是 C1-4 烷基、羟甲基、乙酰氧甲基、二 C1-4 烷氧基甲基、C1-4 烷基氨基甲酰氧甲基或羟基亚氨基甲基;
R3 是 C1-4 烷基、甲酰基、羧基、硝基、-N (R7) (R8)(其中 R7 和 RB 各自是氢、C1-8 烷基、芳基、芳烷基或酰基,或 R7 和 RB 与邻近的氮原子一起构成杂环)、-OR9 或 -SR10(其中 R9 和 R10 各自是氢、C1-8 烷基、芳烷基或酰基);
R4 是氢或-(CH2)mN (Rc) (Rd)(其中每个 Rc 和 Rd 是 C1-4 烷基或芳烷基,或 Rc 和 Rd 与相邻的氮原子一起形成杂环,m 是 1 至 3;
n 为 0 或 1 至 3,包括其光学异构体、非对映异构体和选自药学上可接受的其酸加成盐形式、其水合物形式和其混合物组成的组的化合物、制备所述化合物的方法和含有所述化合物的药物组合物。
二氢咪唑[1,2-a]嘧啶衍生物可作为治疗冠心病和脑循环疾病的药物。